India, Dec. 17 -- ErlySign, a Nagpur-based biotech startup developing India's first salivary biomarker-based screening test for early-stage oral cancer, has announced the successful completion of its large-scale clinical trial conducted across 1,000 patients. With this milestone achieved, the company is now gearing up to introduce its first product to the market by April 2026.

The multi-centre clinical study was conducted across leading cancer care institutions, including HCG Nagpur, Ranchi, Bangalore, and the Regional Cancer Hospital (Rashtrasant Tukdoji Cancer Hospital, Nagpur), a Government of India-recognised centre of excellence.

The interim analyses from this large-scale trial mirrored the findings of ErlySign's earlier small-scal...